HRT Reconsidered: What should you tell patients about it now?
Aschenbrenner
Diane S
DS
Johns Hopkins University School of Nursing, Baltimore, USA. dianea@son.jhmi.edu.
D000368:Aged; D002318:Cardiovascular Diseases / Q000139:chemically induced; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D004966:Estrogens, Conjugated (USP) / Q000009:adverse effects*; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000009:adverse effects*; D008875:Middle Aged; D009726:Nurses; D010353:Patient Education as Topic; D017698:Postmenopause; D012307:Risk Factors; D020521:Stroke / Q000139:chemically induced*
D004338:Drug Combinations; D004966:Estrogens, Conjugated (USP); C466383:Prempro; D017258:Medroxyprogesterone Acetate